Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363258 | 0.93 | RAMP3 (0.59) | OPRD1NTSR1RAMP3CALCR | |
| SCHEMBL30001568 | 0.85 | RAMP3 (0.60) | OPRD1NTSR1RAMP3CALCR | |
| SCHEMBL29521469 | 0.83 | NPY2R (0.61) | OPRD1NTSR1NTSR2 | |
| SCHEMBL8780541 | 0.82 | OPRD1 (0.58) | OPRD1OPRM1NTSR1RAMP3CALCR | |
| SCHEMBL29787464 | 0.79 | OPRM1 (0.58) | OPRD1OPRM1 | |
| SCHEMBL31688354 | 0.79 | NTSR1 (0.61) | OPRD1NTSR1CALCRNTSR2 | |
| SCHEMBL30883233 | 0.79 | NMUR2 (0.68) | — | |
| SCHEMBL30888269 | 0.79 | NPY2R (0.70) | CALCR | |
| SCHEMBL14060698 | 0.78 | NPY1R (0.55) | OPRD1OPRM1NTSR1CALCRNTSR2 | |
| SCHEMBL31182523 | 0.78 | NPY2R (0.65) | CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120030-A1 | Long-Acting Adrenomedullin Derivatives | UNIVERSITY OF MIYAZAKI (JP) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120030-A1 | Long-Acting Adrenomedullin Derivatives | APLNR, NPBWR1, NPPA | OPRD1 1124/4885OPRM1 531/4885NTSR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.